One year of treatment with tozorakimab, AstraZeneca’s experimental therapy, was reported to significantly reduce the annual rate of moderate-to-severe exacerbations, or periods of sudden symptom worsening, in adults with chronic obstructive pulmonary disease (COPD). These are the top-line results from the global Phase 3 MIRANDA clinical trial (NCT06040086),…